The diagnostic accuracy of the biomarker panel was 0.91 for MetS patients and 0.65 for early-stage MetS(+) HCC patients, which were much higher than that of AFP(Figure 5F), indicating that the results with early-stage MetS(+) HCC were similar to the results with small MetS(+) HCC. Here, AFP is linked to hepatocellular carcinoma.